BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 35681659)

  • 1. Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review.
    Cozzi S; Alì E; Bardoscia L; Najafi M; Botti A; Blandino G; Giaccherini L; Ruggieri MP; Augugliaro M; Iori F; Sardaro A; Iotti C; Ciammella P
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
    Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
    Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.
    Horne ZD; Richman AH; Dohopolski MJ; Clump DA; Burton SA; Heron DE
    Lung Cancer; 2018 Jan; 115():1-4. PubMed ID: 29290248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
    Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
    Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
    König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
    Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose hilar and mediastinal stereotactic body radiation therapy for non-small cell lung cancer: Analysis of outcomes in patients receiving one or multiple courses of treatment.
    Kowalchuk RO; Waters MR; Richardson M; Spencer K; Larner JM; Kersh CR
    Thorac Cancer; 2020 Jul; 11(7):2005-2013. PubMed ID: 32469465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results.
    Manabe Y; Shibamoto Y; Baba F; Yanagi T; Iwata H; Miyakawa A; Murai T; Okuda K
    Jpn J Radiol; 2018 Dec; 36(12):719-725. PubMed ID: 30218253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
    Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy for hilar or mediastinal lymph node metastases after definitive treatment with stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer.
    Manabe Y; Shibamoto Y; Baba F; Murata R; Yanagi T; Hashizume C; Iwata H; Kosaki K; Miyakawa A; Murai T; Yano M
    Pract Radiat Oncol; 2012; 2(4):e137-e143. PubMed ID: 24674177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis.
    Nicosia L; Franzese C; Mazzola R; Franceschini D; Rigo M; D'agostino G; Corradini S; Alongi F; Scorsetti M
    Strahlenther Onkol; 2020 Mar; 196(3):213-221. PubMed ID: 31559480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.
    Francolini G; Desideri I; Detti B; Di Cataldo V; Masi L; Caramia G; Visani L; Terziani F; Muntoni C; Lo Russo M; Loi M; Livi L
    Cancer Treat Res Commun; 2019; 19():100124. PubMed ID: 30851645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy.
    Schröder C; Opitz I; Guckenberger M; Stahel R; Weder W; Förster R; Andratschke N; Lauk O
    Front Oncol; 2019; 9():961. PubMed ID: 31616640
    [No Abstract]   [Full Text] [Related]  

  • 13. Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer.
    Levy A; Khalifa J; Martin E; Botticella A; Quevrin C; Lavaud P; Aldea M; Besse B; Planchard D; Barlesi F; Deutsch E; Massabeau C; Doyen J; Le Péchoux C
    Clin Transl Radiat Oncol; 2023 Jul; 41():100637. PubMed ID: 37206411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases.
    Yeung R; Hamm J; Liu M; Schellenberg D
    Radiat Oncol; 2017 Jun; 12(1):105. PubMed ID: 28637480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
    Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
    Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients.
    Arcidiacono F; Aristei C; Marchionni A; Italiani M; Fulcheri CPL; Saldi S; Casale M; Ingrosso G; Anselmo P; Maranzano E
    Br J Radiol; 2020 Nov; 93(1115):20200645. PubMed ID: 32822540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of stereotactic body radiotherapy - is volumetric modulated arc therapy the answer?
    Sapkaroski D; Osborne C; Knight KA
    J Med Radiat Sci; 2015 Jun; 62(2):142-51. PubMed ID: 26229679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
    Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
    J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
    Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.